Have you and your family had your flu shot? It's more important than ever this year! Schedule via MyChart or call for an appointment in SF, the East Bay or San Mateo.

Nicholas Butowski


Avid football – also known as soccer – fan

About me

Dr. Nicholas Butowski is a neuro-oncologist who specializes in brain tumors, neuroimaging, cognitive and rehabilitative neurology, and complementary therapies for neurological disorders. He is director of clinical services in neuro-oncology and a researcher at the Brain Tumor Center.

In his research, Butowski focuses on developing treatments for primary brain tumors as well as methods to ensure good quality of life for patients and to assist them in recovering from or coping with brain injury.

Butowski earned his medical degree at the University of Illinois at Chicago. He completed a residency in neurology and a fellowship in neuro-oncology at UCSF. He is a member of the American Academy of Neurology, American Society of Clinical Oncology and Society for Neuro-oncology.

  • Education

    University of Illinois College of Medicine, 1999

  • Residencies

    UCSF Medical Center, Neurology, 2003

  • Fellowships

    UCSF Medical Center, Neuro-oncology, 2004

  • Academic Title


Compassion is not a virtue; it is a commitment.

Brain Tumor Center

400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143

My reviews


Overall Experience
116 Reviews
I would not want to work with anyone other than Dr Butowski. I completely trust that he has my best interest in mind when making treatment recommendations.
Explained things in a way that was easy to understand
114 Reviews
Did the doctor pay attention to your concerns
114 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
108 Reviews
Knew the important information about your medical history
114 Reviews
The provider showed respect for what you had to say
115 Reviews
The provider spent enough time with me
112 Reviews
Decorative Caduceus

Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

Number of patients who experienced a treatment-related adverse event


Decorative Caduceus

Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry

Time from Gliadel placement to death


Decorative Caduceus

PVSRIPO and Pembrolizumab in Patients With Recurrent Glioblastoma

Objective response rate (comprised of patients meeting an objective radiographic response or ORR): Patients achieving a CR or PR. DOR: Time from first ORR observed (once confirmed) until PD first observed (once confirmed) or deat...


Decorative Caduceus

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Best overall response rate by RANO


Decorative Caduceus

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolom...

Assessment of overall survival. With standard treatment, the median survival of Grade IV patients is expected to be 14.6 months, and the median survival of Grade III is approximately 36 months. Given that we anticipate that approx...


Decorative Caduceus

Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High...

Dose limiting toxicity (DLT) will be defined as any grade-3 or higher neurological toxicity felt to be attributable to the CED infusion of liposomal-irinotecan with gadolinium, as well as any systemic grade-3 or higher hematologic...


Decorative Caduceus

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade...

Incidence and severity of treatment-related adverse events, using standard criteria as well as close clinical follow-up as would be performed normally in this group of participants following vaccinations. All reported or observed ...